ALLMedicine™ Hallucinogens Center

Mar 8th, 2023 - Background: Major Depressive Disorder is one of the most prevalent mental illnesses, leading to substantial personal distress and economical consequences. Pharmacological Treatment is limited and relapse is frequent. Lysergic acid diethylamide (LS...

Feb 23rd, 2023 - Substance use remains a barrier to recovery for young people accessing early intervention services for psychosis. While correlates of use have been explored in populations experiencing a first episode of psychosis (FEP), sample sizes have been sma...

Feb 17th, 2023 - Participants will be randomized to two groups: Psilocybin or Active Placebo. Those in the Psilocybin condition will receive .36 mg/kg of psilocybin. Based on previous research, .36 mg/kg of psilocybin is expected to balance the intention to increa...

Feb 15th, 2023 - Lower-risk substance use guidelines (LRSUGs) are an evidence-based harm reduction strategy used to provide information to people who use drugs so they can reduce harms associated with substance use. This study aimed to identify LRSUGs accessible t...

Feb 12th, 2023 - EDM event attendees are a high-risk population for substance use and associated adverse effects. The aim of this study was to examine substance use at EDM events, focusing on associations between attendance motives and substance use. Sociodemograp...

Mar 8th, 2023 - Background: Major Depressive Disorder is one of the most prevalent mental illnesses, leading to substantial personal distress and economical consequences. Pharmacological Treatment is limited and relapse is frequent. Lysergic acid diethylamide (LS...

Feb 17th, 2023 - Participants will be randomized to two groups: Psilocybin or Active Placebo. Those in the Psilocybin condition will receive .36 mg/kg of psilocybin. Based on previous research, .36 mg/kg of psilocybin is expected to balance the intention to increa...

Jan 6th, 2023 - This study with low-dose LSD comprised 2 substudies in different populations of healthy subjects: Part 1: an open-label dose-escalation study in hallucinogen non-naïve subjects. Part 2: a double blind, placebo controlled, randomised, crossover stu...

Oct 12th, 2022 - N,N-dimethyltryptamine (DMT) is a naturally-occurring psychedelic substance widely used in recreational and spiritual settings in the form of Ayahuasca. Similar to lysergic acid diethylamide (LSD) or psilocybin, DMT is considered a tool to induce ...

Aug 4th, 2022 - One of the most promising lines of investigation for the therapeutic use of hallucinogens in the 1960s and 1970s was in the treatment of drug dependence. The investigators propose to examine psilocybin administration combined with a structured smo...

Nov 14th, 2022 - DENVER (AP) — Colorado voters have passed a ballot initiative to decriminalize psychedelic mushrooms for people 21 and older and to create state-regulated "healing centers" where participants can experience the drug under supervision. Colorado bec...

Oct 12th, 2022 - In 2019 the Defense Advanced Research Projects Agency invested $27 million in the Focused Pharma program to develop new, more efficacious, rapid-acting drugs, including hallucinogens. 1 While Focused Pharma does not include human studies, the Veter.

Sep 19th, 2022 - Women who lived in states with policies that punished women for substance use during pregnancy received worse prenatal and postpartum care, according to a cross-sectional study. Patients in states that considered substance use during pregnancy a f...

Sep 1st, 2022 - One of psychiatry’s long-standing dogmas is that personality disorders are enduring, unchangeable, and not amenable to treatment with potent psychotropics or intensive psychotherapy. I propose that this dogma may soon be shattered.

Aug 16th, 2022 - Recent studies with hallucinogens have raised hopes for an effective drug-based therapy to treat chronic depression. At the German Congress of Psychosomatic Medicine and Psychotherapy, Torsten Passie, MD, PhD, professor of psychiatry and psychothe...